Clinical trials: Throat Carcinoma
Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma
The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC
A phase I/II clinical study of JS004 in subjects with head and neck cancer in China, to evaluate the safety, tolerability, PK, immunogenicity, antitumor activity and biomarkers of JS004, define the RP2D.
- Trial name
- NCT04929080
- Testing
- JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion, JS001 and JS004
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Recurrent or Metastatic Nasopharyngeal Carcinoma
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of Irinotecan Liposome injection combined with S-1 in patients with recurrent (unable to local curative treatment) or metastatic NPC who failed…
- Trial name
- NCT06657690
- Testing
- Irinotecan liposome, S-1
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sun Yat-sen University
Oral Cavity Cancer, Dysphagia
Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
While the group of oral cavity cancer (OCC) survivors continue to increase, surgeons and oncologist intensify their search for improved treatment and rehabilitation methods to reduce the morbidity of management without…
- Conditions
- Oral Cavity Cancer, Dysphagia, Quality of Life
- Trial name
- NCT06407570
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Nasopharyngeal Neoplasms
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy and safety of Apatinib as maintenace therapy for Nasopharyngeal Carcinoma With Metastasis after Chemoradiotherapy, including progress free survival(PFS)、overall survival (OS)、Quality of life…
- Trial name
- NCT03180476
- Testing
- Apatinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Injury; Temporal Region
Dose Constraints for the Temporal Lobes of Intensity-modulated Radiotherapy Treatment Plans for Nasopharyngeal Carcinoma
Radiation-induced temporal lobe injury (TLI) is usually devastating to patients; however, there is a poor understanding of TLI in nasopharyngeal carcinoma (NPC) patients treated with IMRT.
- Trial name
- NCT03539250
- Testing
- IMRT
- Volunteers
- 350 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Nasopharyngeal Carcinoma, Local Recurrence
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence.
- Trial name
- NCT07331428
- Testing
- MRG003, Tislelizumab, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Individualized Elective Neck Irradiation Based on MRI in NPC Patients
Currently, most protocols of nasopharyngeal carcinoma (NPC) of various research bodies such as the Radiation Therapy Oncology Group require routine elective irradiation to the retropharyngeal area and to levels II-V lymph nodal…
- Trial name
- NPC-CTVn (NCT02642107)
- Testing
- Elective neck irradiation, Whole neck irradiation
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced nasopharyngeal…
- Trial name
- NCT03427359
- Testing
- cisplatin, capecitabine
- Volunteers
- 65 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
Nasopharyngeal Carcinoma
Umbrella Biomarker-Guided Therapy in NPC
This is a phase 2, open-label, umbrella study, with the purpose to evaluate the therapeutic efficacy and safety of chemoradiotherapy in combination with immunotherapy and/or targeted treatment in high-risk locoregionally advanced…
- Trial name
- NCT04605562
- Testing
- GP+DDP, Palbociclib, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve survival in locoregionally advanced nasopharyngeal carcinoma compared to best supportive care.
- Trial name
- DIPPER (NCT03427827)
- Testing
- Camrelizumab
- Where
- 11 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm open-label, phase II study to evaluate the anti-tumor activity, safety, PK and immunogenicity of AK105 (Anti-PD1 antibody) in patients with metastatic nasopharyngeal carcinoma who have progressed…
- Trial name
- NCT03866967
- Testing
- AK105
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- Akeso
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population.
- Trial name
- NCT03639467
- Testing
- Anlotinib plus gemcitabine/cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Salivary Gland Cancer, Nasopharyngeal Carcinoma
Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis
Nasopharyngeal carcinoma (NPC) is the tenth leading cancers in Taiwan and investigating its biomarker is important for understanding the mechanism of its pathogenesis.
- Trial name
- NCT02401763
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Nasopharyngeal Carcinoma
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment…
- Trial name
- NCT05341193
- Testing
- Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancer, Epstein Barr Virus Infections
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
This clinical study is looking at a vaccine called MVA-EBNA1/LMP2. This is a new vaccine that has already been studied in small number of cancer patients.
- Trial name
- NCT01800071
- Testing
- MVA-EBNA1/LMP2 vaccine
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cancer Research UK
Refractory Nasopharyngeal Carcinoma
Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin. It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has…
- Trial name
- NCT00484601
- Testing
- Ifosfamide, Doxorubicin
- Where
- Singapore
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lip, Oral Cavity Squamous Cell Carcinoma
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck.
- Conditions
- Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx
- Trial name
- NCT03854032
- Testing
- Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Thomas Jefferson University
Nasopharyngeal Carcinoma
A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average.
- Trial name
- NCT05949749
- Testing
- Epitope exploration
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Cancer
NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx
RATIONALE: Cancers of the oral cavity represent 30% of head and neck carcinomas in the western world. The oropharynx is the posterior continuation of the oral cavity and connects with the nasopharynx (above) and laryngopharynx…
- Trial name
- NCT01946867
- Testing
- NBTXR3 activated by IMRT
- Where
- 20 sites in France, Hungary and 2 more
- Volunteers
- 75 people
- Sponsor
- Nanobiotix